EUCTR2008-004760-39-IT进行中（未招募）不适用
A Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin - ND
Schering Plough Institute, A Division of Schering Corporation0 个研究点目标入组 198 人开始时间: 2009年3月11日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 198
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects with CHC (genotype 1) who failed to achieve SVR on prior adequate treatment with any peginterferon alfa and ribavirin but demonstrated interferon responsiveness (a decrease in HCV-RNA viral load ≥2 log10 by TW 12 or undetectable HCV-RNA at End of Treatment [EOT]) will be selected for the study. Inclusion Criteria for Interferon-Responsive CHC Patients Who Have Failed Treatment: 1. For inclusion in the study, subjects must have a qualifying regimen defined as PEG2a/R or PEG2b/R for a minimum of 12 weeks. If a subject has received more than one such regimen, the most recent regimen is considered the qualifying regimen. Note: Maintenance therapy, following failure of qualifying therapy, with any interferon alfa is acceptable; however, the subject must have discontinued the maintenance therapy at least 1 month prior to the Screening Visit. 2. During the qualifying regimen, subjects must have either: a. A documented undetectable HCV-RNA within 30 days of EOT and a subsequent detectable HCVRNA during follow-up OR b. A documented decline in HCV-RNA by ≥2 log10 by TW 12. Note: For subjects who did not participate in Schering-Plough Research Institute (SPRI) protocols, qualifying virology reports and documentation of qualifying previous treatment regimen must be completely deidentified and faxed to the sponsor`s project physician for confirmation that the documentation meets protocol-specified criteria. 3. Subject must have previously documented CHC genotype 1 infection. Subjects with other or mixed genotypes are not eligible. The HCV-RNA result obtained from the central laboratory at the Screening Visit must confirm genotype 1 infection and be ≥10,000 IU/mL. 4. Subject must have a liver biopsy with histology consistent with CHC and no other etiology. Copies of the pathology report and slides are required for the subject to be included in the study. The study site must be able to access the pathology report and histology slides prior to subject randomization. Two unstained slides are preferred; however, one slide stained with hematoxylin plus eosin (H & E) plus one slide stained with Masson?s trichrome will be accepted (slides should be reviewed by the investigator to confirm adequacy). The central pathologist?s reading will be used for analysis purposes. a. If no cirrhosis is present: The liver biopsy must be within 3 years of the Screening Visit. b. If cirrhosis is present: Any historic liver biopsy demonstrating cirrhosis will be accepted regardless of length of time since biopsy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subjects known to be coinfected with the human immunodeficiency virus (HIV) or hepatitis B virus (hepatitis B surface antigen [HBsAg] positive) and/or demonstrating signs and symptoms consistent with co-infection. 2. Subjects who required discontinuation of previous interferon or ribavirin regimen for an adverse event considered by the investigator to be possibly or probably related to ribavirin and/or interferon. 3. Treatment with ribavirin within 90 days and any interferon alfa within 1 month of Screening. 4. Treatment for hepatitis C with any investigational medication. Prior treatment with herbal remedies with known hepatotoxicity is exclusionary. All herbal remedies used for hepatitis C treatment other than silymarin (milk thistle) must be discontinued before Day 1. 5. Treatment with any investigational drug within 30 days of the randomization visit in this study.
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/RibaviriChronic Hepatitis CMedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis CMedDRA version: 9.1 Level: PT Classification code 10019744 Term: Hepatitis CMedDRA version: 9.1 Level: SOC Classification code 10021881 Term: Infections and infestationsMedDRA version: 9.1 Level: SOC Classification code 10019805 Term: Hepatobiliary disordersEUCTR2007-005151-42-FRSchering Plough Research Institute, A Division of Schering Corporation375
进行中（未招募）
1 期
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/RibaviriChronic Hepatitis CMedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis CMedDRA version: 9.1 Level: PT Classification code 10019744 Term: Hepatitis CMedDRA version: 9.1 Level: SOC Classification code 10021881 Term: Infections and infestationsMedDRA version: 9.1 Level: SOC Classification code 10019805 Term: Hepatobiliary disordersEUCTR2007-005151-42-GBSchering Plough Research Institute, A Division of Schering Corporation375
进行中（未招募）
不适用
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/RibaviriEUCTR2007-005151-42-PTSchering Plough Research Institute, A Division of Schering Corporation375
进行中（未招募）
1 期
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/RibaviriChronic Hepatitis CMedDRA version: 9.1 Level: LLT Classification code 10008912 Term: Chronic hepatitis CMedDRA version: 9.1 Level: PT Classification code 10019744 Term: Hepatitis CMedDRA version: 9.1 Level: SOC Classification code 10021881 Term: Infections and infestationsMedDRA version: 9.1 Level: SOC Classification code 10019805 Term: Hepatobiliary disordersEUCTR2007-005151-42-BESchering Plough Research Institute, A Division of Schering Corporation375
进行中（未招募）
不适用
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/RibaviriEUCTR2007-005151-42-DESchering Plough Research Institute, A Division of Schering Corporation375